# CMS Opened the Door for Cannabinoids. ACOs Still Need the Operating Model > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cms-opened-the-door-for-cannabinoids-acos-still-need-the-operating-model/ > **Published:** 2026-06-17T07:11:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:12-04:00 > **Clinical Summary:** CMS opened cannabinoid reimbursement for ACOs. Learn clinical protocols and operational requirements for safe integration. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyCBDTHCSafetyResearchIndustryMental Health Why This Matters Accountable Care Organizations now face a critical operational question about whether and how to integrate [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) into their care delivery models following CMS’s openness to coverage, which directly affects clinicians’ ability to offer these therapies to eligible patients. Clinicians need clarity on their ACO’s policies and infrastructure for cannabinoid prescribing, [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/), and monitoring to safely incorporate these options into evidence-based treatment plans. Without standardized operating procedures across ACOs, patients may experience inconsistent access to cannabinoid therapies based on their healthcare system rather than clinical indication or evidence. Clinical Summary The Centers for Medicare and Medicaid Services has created coverage pathways for certain cannabinoid products, potentially expanding access for Medicare beneficiaries, though Accountable Care Organizations (ACOs) and health systems remain uncertain about operational implementation. Clinical ambiguity persists regarding the distinction between THC-containing products and [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) like CBD, which affects prescribing practices and [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/). ACOs currently lack clear clinical guidelines, billing frameworks, and care coordination protocols necessary to safely integrate cannabinoid therapies into their existing treatment algorithms. This regulatory opening without corresponding operational guidance creates a gap between policy intent and practical clinical delivery, potentially limiting [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) despite formal coverage approval. Clinicians should anticipate increased patient inquiries about cannabinoid options but should recognize that coverage alone does not establish clear clinical protocols or evidence-based dosing standards within their health systems. Health systems and ACOs would benefit from developing internal cannabinoid policies that define appropriate indications, establish safety monitoring procedures, and clarify [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/) before widespread prescribing begins. Clinical Perspective 🏥 As accountable care organizations navigate the Centers for Medicare and Medicaid Services’ recent openness to cannabinoid reimbursement, clinicians should recognize that regulatory approval pathways do not automatically translate into clear clinical guidance or operational readiness at the point of care. The distinction between THC-containing products and [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) remains poorly understood among many practitioners and patients alike, creating potential for inappropriate prescribing or unrealistic expectations about efficacy and safety. Evidence for most cannabinoid therapies outside of FDA-approved formulations like epidiolex remains limited, heterogeneous, or derived from small studies, making it difficult to establish clear indications and dosing protocols. Until healthcare organizations develop standardized cannabinoid assessment and monitoring frameworks aligned with their existing [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) or neurology protocols, individual clinicians may struggle to integrate these agents responsibly into treatment plans. Given current knowledge gaps, providers should approach cannabinoid 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20CMS%20Opened%20the%20Door%20for%20Cannabinoids.%20ACOs%20Still%20Need%20the%20Operating%20Model%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59413)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59413)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20CMS%20Opened%20the%20Door%20for%20Cannabinoids.%20ACOs%20Still%20Need%20the%20Operating%20Model%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59413)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://cannatechtoday.com/cms-opened-the-door-for-cannabinoids-acos-still-need-the-operating-model/](https://cannatechtoday.com/cms-opened-the-door-for-cannabinoids-acos-still-need-the-operating-model/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).